# ARCT catalysts: Arcturus Therapeutics Holdings Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/arct/catalysts

> Arcturus Therapeutics Holdings Inc. (ARCT) has 4 upcoming catalysts. The next is the ARCT-2601 topline data readout, Q1 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, quarter only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for ARCT?

Arcturus Therapeutics Holdings Inc. (ARCT) has 4 upcoming catalysts. The next is the ARCT-2601 topline data readout, Q1 2027. Press release filed with the SEC (EX-99): "Arcturus plans to initiate ARCT-2601 Phase 2 dosing in Q1 2027, with top-line data expected in" [Calendar and source filings](https://sec-api.dev/companies/arct/catalysts)

Source: Press release filed with the SEC (EX-99), accession 0001193805-26-001439, https://www.sec.gov/Archives/edgar/data/1768224/000119380526001439/e665874_ex99-1.htm (retrieved 2026-11-12). Last confirmed 2026-11-05. Cite: https://sec-api.dev/companies/arct/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | Arcturus Therapeutics Holdings Inc. |
| Ticker | ARCT (Nasdaq) |
| SEC CIK | 1768224 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/arct |

## Cash runway

Cash $184.8M as of 2026-09-30; quarterly burn $6.9M; about 80.3 months of runway at that rate (XBRL company facts, accession 0001193125-26-449901).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Sep 2023 | [KOSTAIVE (ARCT-2301) trial start](https://sec-api.dev/pdufa/arct-2301) | ARCT |  | completed | "In September 2023, Meiji initiated a Phase 3 clinical study with ARCT-2301, a bivalent version of KOSTAIVE (ancestral strain and Omicron BA.4/5) to further support immunogenicity and safety data for our self-amplifying mRNA platform, which may facilitate the timely release of future seasonal updates of our COVID-19 vaccine against evolving variants of concern." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1768224/000095017025034787/arct-20241231.htm)) |
| Dec 2024 | [Fibrosis trial start](https://sec-api.dev/pdufa/fibrosis) | ARCT | Class I | completed | "In December 2024, we initiated dosing in our ARCT-032 Phase 2 multiple ascending dose study designed to identify a safe and effective dose in Class I (null) and other CF participants who do not benefit from CFTR modulators." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1768224/000119312526088391/arct-20251231.htm)) |
| March 6, 2025 | [Arcturus Therapeutics Holdings Inc. earnings report](https://sec-api.dev/companies/arct/catalysts) | ARCT |  | completed | "Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced its financial results for the fourth quarter ended December 31, 2024, and provided corporate updates." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1768224/000119380525000275/e664243_ex99-1.htm)) |
| Q2 2025 | [Arcturus Therapeutics Holdings Inc. interim data readout](https://sec-api.dev/companies/arct/catalysts) | ARCT |  | scheduled | ""We continue to progress our flagship rare disease programs and look forward to sharing meaningful Phase 2 interim data from our cystic fibrosis (CF) and ornithine transcarbamylase (OTC) deficiency programs in Q2 2025," said Joseph Payne, President & CEO of Arcturus Therapeutics." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1768224/000119380525000275/e664243_ex99-1.htm)) |
| mid-2025 | [Fibrosis interim data readout](https://sec-api.dev/pdufa/fibrosis) | ARCT |  | scheduled | "ARCT-032 (CF) Phase 2 interim data from first two cohorts expected in mid-2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1768224/000119380525000630/e664482_ex99-1.htm)) |
| May 12, 2025 | [Arcturus Therapeutics Holdings Inc. earnings report](https://sec-api.dev/companies/arct/catalysts) | ARCT |  | completed | "Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced its financial results for the first quarter ended March 31, 2025, and provided corporate updates." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1768224/000119380525000630/e664482_ex99-1.htm)) |
| June 30, 2025 | [Deficiency interim data readout](https://sec-api.dev/pdufa/deficiency) | ARCT |  | completed, positive | "On June 30, 2025, we announced positive multiple dosing data of ARCT-810 from two Phase 2 studies: (i) a completed placebo-controlled study in Europe that randomized eight participants to ARCT-810 0.3 mg/kg or placebo; and (ii) an open-label multiple ascending dose study in the U.S., with interim data from the initial three completed participants." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1768224/000119312526088391/arct-20251231.htm)) |
| August 11, 2025 | [Arcturus Therapeutics Holdings Inc. earnings report](https://sec-api.dev/companies/arct/catalysts) | ARCT |  | completed | "Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics and infectious disease vaccines, today announced its financial results for the second quarter ended June 30, 2025, and provided corporate updates." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1768224/000119380525001175/e664773_ex99-1.htm)) |
| November 10, 2025 | [Arcturus Therapeutics Holdings Inc. earnings report](https://sec-api.dev/companies/arct/catalysts) | ARCT |  | completed | "Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics and infectious disease vaccines, today announced its financial results for the third quarter ended September 30, 2025, and provided corporate updates." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1768224/000119380525001555/e664953_ex99-1.htm)) |
| 1H 2026 | [Fibrosis trial start](https://sec-api.dev/pdufa/fibrosis) | ARCT |  | scheduled | "Arcturus' ARCT-032, a once-daily inhaled mRNA therapeutic candidate for CF, is on track to initiate a new 12-week Phase 2 clinical study in H1 2026 enrolling up to 20 Class I" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1768224/000119380526000214/e665201_ex99-1.htm)) |
| March 3, 2026 | [Arcturus Therapeutics Holdings Inc. earnings report](https://sec-api.dev/companies/arct/catalysts) | ARCT |  | completed | "Therapeutics Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Pipeline Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1768224/000119380526000214/e665201_ex99-1.htm)) |
| May 1, 2026 | [Arcturus Therapeutics Holdings Inc. earnings report](https://sec-api.dev/companies/arct/catalysts) | ARCT |  | completed | "Therapeutics Announces First Quarter 2026 Financial Results and Pipeline Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1768224/000119380526000573/e665435_ex99-1.htm)) |
| June 2026 | [ARCT-810 primary completion](https://sec-api.dev/pdufa/arct-810) | ARCT | OTC Deficiency; Ornithine Transcarbamylase Deficiency; OTCD | delayed | "NCT06488313 (A Study to Evaluate the Pharmacodynamics and Safety of ARCT-810 in Participants With OTCD): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-06-01 (ESTIMATED); Lead Sponsor Arcturus Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06488313)) |
| August 6, 2026 | [Arcturus Therapeutics Holdings Inc. earnings report](https://sec-api.dev/companies/arct/catalysts) | ARCT |  | completed | "Therapeutics Announces Second Quarter 2026 Financial Results and Pipeline Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1768224/000119380526001039/e665679_ex99-1.htm)) |
| November 5, 2026 | [Arcturus Therapeutics Holdings Inc. earnings report](https://sec-api.dev/companies/arct/catalysts) | ARCT |  | completed | "Therapeutics Announces Third Quarter 2026 Financial Results and Pipeline Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1768224/000119380526001439/e665874_ex99-1.htm)) |
| Q1 2027 | [ARCT-2601 topline data readout](https://sec-api.dev/pdufa/arct-2601) | ARCT |  | scheduled | "Arcturus plans to initiate ARCT-2601 Phase 2 dosing in Q1 2027, with top-line data expected in" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1768224/000119380526001439/e665874_ex99-1.htm)) |
| June 2027 | [ARCT-032 primary completion](https://sec-api.dev/pdufa/arct-032) | ARCT | Cystic Fibrosis; CFTR Gene Mutation | scheduled | "NCT06747858 (Safety, Tolerability and Efficacy Study of ARCT-032 in People With Cystic Fibrosis): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-06 (ESTIMATED); Lead Sponsor Arcturus Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06747858)) |
| Jun to Sep 2027 | [ARCT-032 topline data readout](https://sec-api.dev/pdufa/arct-032) | ARCT | Cystic Fibrosis; CFTR Gene Mutation | scheduled | "NCT06747858 (Safety, Tolerability and Efficacy Study of ARCT-032 in People With Cystic Fibrosis): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-06 (ESTIMATED); Lead Sponsor Arcturus Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06747858)) |
| 2H 2027 | [ARCT-2601 topline data readout](https://sec-api.dev/pdufa/arct-2601) | ARCT |  | scheduled | "ARCT-2601 (OTC Deficiency), the first mRNA therapeutic candidate utilizing LUNAR 2.0™, Phase 2 dosing planned to begin Q1 2027; top-line data H2 2027" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1768224/000119380526001439/e665874_ex99-1.htm)) |

## Drugs

- [ARCT-032](https://sec-api.dev/pdufa/arct-032): Cystic Fibrosis
- [KOSTAIVE (ARCT-2301)](https://sec-api.dev/pdufa/arct-2301): 
- [ARCT-2601](https://sec-api.dev/pdufa/arct-2601): 
- [ARCT-810](https://sec-api.dev/pdufa/arct-810): OTC Deficiency
- [Deficiency](https://sec-api.dev/pdufa/deficiency): 
- [Fibrosis](https://sec-api.dev/pdufa/fibrosis): class i

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/arct/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "ARCT catalysts: Arcturus Therapeutics Holdings Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/arct/catalysts

```bibtex
@misc{secapidev_companies_arct_catalysts_20261116,
  title        = {ARCT catalysts: Arcturus Therapeutics Holdings Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/arct/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_arct_catalysts_20261116","title":"ARCT catalysts: Arcturus Therapeutics Holdings Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/arct/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
